Click here for slides on this topic


Insulin glargine

A long-acting insulin for glycemic control in diabetes.
The following content matched the glossary term: Insulin glargine

CompanionSetType2DiabetesMedications

Top

Patient education companion set featuring handouts on DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and medications used to treat type 2 diabetes (English and Spanish)

Medications Used To Treat Type 2 Diabetes

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose.

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

Medicamentos para el tratamiento de la diabetes tipo 2

Top

Patient education handout showing medications used to treat type 2 diabetes and where and how these medications work in the body to lower blood glucose—in Spanish.

ADA 2016 Type 1 Diabetes Pharmacologic Therapy

Top

Type 1 diabetes treatment options from the 2016 ADA guidelines

ADA 2016 Insulin & Glucose Monitoring

Top

Recommendations for insulin and glucose monitoring in diabetes (SMBG) from the 2016 ADA guidelines

ADA 2016 Type 2 Diabetes Pharmacologic Therapy

Top

Pharmacologic treatment options for type 2 diabetes from the 2016 ADA guidelines

Treating the Patient With Type 2 Diabetes and Renal Impairment – References

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities  

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

Treating the Patient With Type 2 Diabetes and Renal Impairment – Key Take-Home Messages

Top

Patient case: 58-Year-Old African-American Woman with Type 2 Diabetes, Worsening Kidney Function, and Cardiometabolic Comorbidities

Presented by NDEI Education Council Member, Vivian A. Fonseca, MD

 

1 2 3 4 5 6 7 Next 

Slide Library Results

Search Results for: Insulin glargine Slides Found: 74
HEART2D: Primary Outcome Vs Days in Trial by Treatment Strategy
HEART2D Trial: A1C Values at Each Visit for 60 Months
ORIGIN Trial: Design
ORIGIN Trial: Baseline Characteristics (1 of 2)
ORIGIN Trial: Baseline Characteristics (2 of 2)
ORIGIN Trial: Results
ORIGIN Glargine Trial: Design
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
ORIGIN Omega-3 Fatty Acid Trial: Design
ORIGIN Omega-3 Fatty Acid Trial: Primary and Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Additional Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Primary Outcome—CV Death
ORIGIN Omega-3 Fatty Acid Trial: Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Mean Change in Lipids
ORIGIN Omega-3 Fatty Acid Trial: Conclusions
EASIE Trial: Design
EASIE Trial: Study and Enrollment Profile
EASIE Trial: Efficacy Population Primary Outcome at Week 24—Change in A1C from Baseline
EASIE Trial: Efficacy Population A1C <7.0% and <6.5% Week 24
EASIE Trial: Safety Population Hypoglycemia and Adverse Events
ORIGIN: Design
ADA/Endocrine Society: Strategies for Preventing Hypoglycemia (2 of 2)
ORIGIN-GRACE: Design
ORIGIN-GRACE: Primary and Secondary Outcomes
ORIGIN-GRACE: Select Baseline Characteristics
ORIGIN-GRACE: No Difference in Annualized Change in Max CIMT for 12 Carotid Artery Segments with Glargine or Omega-3 Fatty Acid
ORIGIN-GRACE: Glargine, Not Omega-3 Fatty Acid, Improves Annualized Change in Max CIMT
ORIGIN-GRACE: No Difference in Annualized Change in Max Far Wall CIMT for Glargine or Omega-3 Fatty Acid
ORIGIN-GRACE: Major Cardiovascular Events
ORIGIN-GRACE: Summary of Findings
ORIGIN-GRACE: Eligibility Criteria and Trial Profile
Efficacy of Twice-Daily Exenatide Added to Basal Insulin for A1C Reduction: Design
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo : A1C Reduction at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Target A1C Levels at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Body Weight 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Hypoglycemia at 30 Wks
Twice-Daily Exenatide Vs Placebo Added to Basal Insulin: Adverse Events
Liraglutide Reduces A1C Irrespective of Baseline A1C
Diabetes Pregnancy Guidelines Insulin Therapy | NDEI
Diabetes Pregnancy Guidelines Preconception Insulin | NDEI
Basal Insulin Glycemic Control A1C Type 2 Diabetes | NDEI
DURATION-3 & LEAD-5 Post-Hoc Analysis Insulin Type 2 Diabetes PPT | NDEI
A1C Reduction GLP-1 RAs & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Similar A1C Goal Achievement GLP-1 RA & Glargine DURATION-3 & LEAD-5 | NDEI
Weight Loss With GLP-1 RA & Increase With Glargine in DURATION-3 & LEAD-5 | NDEI
Hypoglycemia With GLP-1 RA & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Insulin Glargine Neutral on CV Outcomes & Cancer Diabetes ORIGIN | NDEI
Neutral Omega-3 Effect on CV Outcomes in ORIGIN Diabetes | NDEI
Insulin Glargine A1C Reduction Type 2 Diabetes PPT | NDEI
AWARD-2: Once-Weekly Dulaglutide Vs Insulin Glargine Type 2 Diabetes | NDEI
Lower A1C With Dulaglutide Vs Insulin Glargine AWARD-2 Results | NDEI
Saxagliptin Not Associated With Fractures in SAVOR-TIMI 53 Analysis | NDEI
Safety of Dulaglutide & Insulin Glargine Pancreatitis AWARD-2 | NDEI
AWARD-2 Design Dulaglutide Vs Insulin Glargine Type 2 Diabetes | PPT
AWARD-2: Lower A1C With Dulaglutide Vs Insulin Glargine Type 2 Diabetes | NDEI
AWARD-2 Similar Adverse Events With Dulaglutide & Insulin Glargine Type 2 Diabetes | NDEI
ORIGINALE No Increase in CV Events or Cancer with Insulin Glargine Diabetes | NDEI
ORIGINALE No Effect of Omega-3 Fatty Acids on CV Outcomes | NDEI
ORIGINALE A1C Reduction With Insulin Glargine Type 2 Diabetes | NDEI